Macrogenics (NASDAQ: MGNX)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-01 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.970 | -0.670 | 0.3000 | ||||
REV | 13.770M | 26.007M | 12.237M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Macrogenics (NASDAQ: MGNX) through any online brokerage.
Other companies in Macrogenics’s space includes: Outlook Therapeutics (NASDAQ:OTLK), AVEO Pharmaceuticals (NASDAQ:AVEO), Innate Pharma (NASDAQ:IPHA), Vaxxinity (NASDAQ:VAXX) and Jounce Therapeutics (NASDAQ:JNCE).
The latest price target for Macrogenics (NASDAQ: MGNX) was reported by SVB Leerink on Tuesday, August 9, 2022. The analyst firm set a price target for 12.00 expecting MGNX to rise to within 12 months (a possible 195.57% upside). 15 analyst firms have reported ratings in the last year.
The stock price for Macrogenics (NASDAQ: MGNX) is $4.06 last updated Today at August 19, 2022, 8:00 PM UTC.
There are no upcoming dividends for Macrogenics.
Macrogenics’s Q3 earnings are confirmed for Tuesday, November 1, 2022.
There is no upcoming split for Macrogenics.
Macrogenics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.